Involvement of inflammatory markers in pathogenesis of venous thromboembolism


Inflammation of the venous wall is involved in thrombogenesis, thrombus resolution, wall remodeling and the post-thrombotic syndrome. Different mechanisms are involved in both arterial and venous thrombosis and patients with atherothrombosis hold a higher risk of venous thrombosis. Although inflammation may represent the connection between arterial and venous thrombosis, it is not yet sure if it is the cause or consequence of venous thrombosis. Consequently, the relationships between inflammation markers as indicators of the inflammatory process and clinical venous thromboembolism need to be investigatd. For example, inflammation mediators such as the pro-inflammatory cytokines interleukin 8 (IL-8), IL-6, monocyte chemotactic protein 1 (MCP-1), C Reactive Protein (CRP), vascular cell adhesion molecule 1 (VCAM-1), intercellular adhesion molecule 1 (ICAM-1), matrix metalloproteinases and tumor necrosis factor alpha (TNF alpha) are all involved in thrombogenesis. Studies of venous thromboembolism on animal models proved that there are specific phases of the inflammatory process in venous thromboembolism and thrombus resolution. Knowing the molecular and immunologic mechanisms, identifying and understanding the inflammation markers which are relevant for venous thrombosis, can help to target specific pathways and to develop future therapies of this disease

If the inline PDF is not rendering correctly, you can download the PDF file here.

  • 1. Poredos P, Jezovnik MK. The Role of Inflammation in Venous Thromboembolism and the Link Between Arterial and Venous Thrombosis. Int Angiol 2007;26:306-11.

  • 2. Fox EA, Kahn SR. The relationship between inflammation and venous thrombosis. A systematic review of clinical studies. Thromb Haemost 2005;94:362-5. DOI: 10.1160/th05-04-0266

  • 3. Jo JY, Lee MY, Lee JW, Rho BH, Choi WI. Leukocytes and systemic inflammatory response syndrome as prognostic factors in pulmonary embolism patients. BMC Pulm Med [Internet] 2013 [cited 2017 Jan02];13:74[8p].

  • 4. Zhang Y, Yang Y, Chen W, Liang L, Zhai Z, Guo L, et al. Hypertension associated with venous thromboembolism in patients with newly diagnosed lung cancer. Sci Rep [Internet] 2016 [cited 2017 Jan 02];6:19603[7p]. Available from: PubMed Central.

  • 5. Unizony S, Lu N, Tomasson G, Zhang Y, Merkel PA, Stone JH, et al. Temporal Trends of Venous Thromboembolism Risk Before and After Diagnosis of Giant Cell Arteritis. Arthritis Rheumatol 2017 Jan;69(1):176-84. DOI: 10.1002/art.39847

  • 6. Goljan-Geremek A, Geremek M, Puscinska E, Sliwinski P. Venous thromboembolism and sarcoidosis: co-incidence or coexistence? Cent Eur J Immunol 2015;40(4):477-80. DOI: 10.5114/ceji.2015.56972

  • 7. Lee DK, Kim HJ, Lee DH. Incidence of Deep Vein Thrombosis and Venous Thromboembolism following TKA in Rheumatoid Arthritis versus Osteoarthritis: A Meta-Analysis. PLoS One. [Internet] 2016 [cited 2017 Jan 02];2;11(12)[10p].

  • 8. Nowak M, Krolak-Nowak K, Sobolewska-Wlodarczyk A, Fichna J, Wlodarczyk M. Elevated risk of venous thromboembolic events in patients with inflammatory myopathies. Vasc Health Risk Manag 2016 Jun 3;12:233-8.

  • 9. Kubota Y, McAdams-DeMarco M, Folsom AR. Serum uric acid, gout, and venous thromboembolism: The atherosclerosis risk in communities study. Thromb Res 2016 Aug;144:144-8. DOI: 10.1016/j.thromres.2016.06.020

  • 10. Silvestri E, Scalera A, Emmi G, Squatrito D, Ciucciarelli L, Cenci C, et al. Thrombosis in Autoimmune Diseases: A Role for Immunosuppressive Treatments? Semin Thromb Hemost 2016 Sep;42(6):650-61. DOI: 10.1055/s-0036-1579642

  • 11. Ungprasert P, Wijarnpreecha K, Tanratana P. Risk of venous thromboembolism in patients with celiac disease: A systematic review and meta-analysis. J Gastroenterol Hepatol 2016 Jul;31(7):1240-5. DOI: 10.1111/jgh.13282

  • 12. Lentz SR. Thrombosis in the setting of obesity or inflammatory bowel disease. Blood 2016 Nov;128(20):2388-94. DOI: 10.1182/blood-2016-05-716720

  • 13. Horvei LD, Grimnes G, Hindberg K, Mathiesen EB, Njolstad I, Wilsgaard T, et al. C-reactive protein, obesity, and the risk of arterial and venous thrombosis. J Thromb Haemost 2016 Aug;14(8):1561-71. DOI: 10.1111/jth.13369

  • 14. Christensen DH, Horvath-Puho E, Thomsen RW, Knudsen ST, Dekkers O, Prandoni P, et al. Venous thromboembolism and risk of cancer in patients with diabetes mellitus. J Diabetes Complications 2016 May- Jun;30(4):603-7. DOI: 10.1016/j.jdiacomp.2016.01.011

  • 15. Matos MF, Lourenco DM, Orikaza CM, Bajerl JAH, Noguti MAE, Morelli VM. The role of IL-6, IL-8 and MCP-1 and their promoter polymorphisms IL-6 -174GC, IL-8 -251AT and MCP-1 -2518AG in the risk of venous thromboembolism: A case-control study. Thromb Res 2011;128:216-20. DOI: 10.1016/j.thromres.2011.04.016

  • 16. Pabinger I, Thaler J, Ay C. Biomarkers for prediction of venous thromboembolism in cancer. Blood 2013;122(12):2011-8. DOI: 10.1182/ blood-2013-04-460147

  • 17. Reitsma PH, Rosendaal FR. Activation of innate immunity in patients with venous thrombosis: the Leiden Thrombophilia Study. J Thromb Haemost 2004;2:619-22. DOI: 10.1111/j.1538-7836.2004.00689.x

  • 18. Roumen-Klappe EM, den Heijer M, van Uum SHM, van der Ven-Jongekrijg J, van der Graaf F, Wollersheim H. Inflammatory response in the acute phase of deep vein thrombosis. J Vasc Surg 2002;35:701-6. DOI: 10.1067/mva.2002.121746

  • 19. Saghazadeh A, Hafizi S, Rezaei N. Inflammation in venous thromboembolism: Cause or consequence? Int Immunopharmacol 2015 Sep;28(1):655-65. DOI: 10.1016/j.intimp.2015.07.044

  • 20. Saghazadeh A, Rezaei N. Inflammation as a cause of venous thromboembolism. Crit Rev Oncol Hematol 2016 Mar;99:272-85. DOI: 10.1016/j.critrevonc. 2016.01.007

  • 21. van Aken,BE, Reitsma PH, Rosendaal FR. Interleukin 8 and venous thrombosis: evidence for a role of inflammation in thrombosis. Br J Haematol 2002;116: 173-7. DOI: 10.1046/j.1365-2141.2002.03245.x

  • 22. Zagorski J, Gellar MA, Obraztsova M, Kline JA, Watts JA. Inhibition of CINC-1 Decreases Right Ventricular Damage Caused by Experimental Pulmonary Embolism in Rats. J Immunol 2007;179:7820-6. DOI: 10.4049/jimmunol.179.11.7820

  • 23. Rabinovich A, Cohen JM, Cushman M, Kahn SR. Association between inflammation biomarkers, anatomic extent of deep venous thrombosis, and venous symptoms after deep venous thrombosis. J Vasc Surg Venous Lymphat Disord 2015 Oct;3(4):347-53. DOI: 10.1016/j.jvsv.2015.04.005

  • 24. Jacobs B, Obi A, Wakefield T. Diagnostic biomarkers in venous thromboembolic disease. J Vasc Surg Venous Lymphat Disord 2016 Oct;4(4):508-17. DOI: 10.1016/j.jvsv.2016.02.005

  • 25. Cushman M, O’Meara ES, Heckbert SR, Zakai NA, Rosamond W, Folsom AR. Body size measures, hemostatic and inflammatory markers and risk of venous thrombosis: The Longitudinal Investigation of Thromboembolism Etiology. Thromb Res 2016 Aug;144:127-32. DOI: 10.1016/j.thromres.2016.06.012

  • 26. Cushman M, Callas PW, Allison MA, Criqui MH. Inflammation and peripheral venous disease. The San Diego Population Study. Thromb Haemost 2014;112(3):566-72. DOI: 10.1160/TH13-10-0860

  • 27. Hou H, Ge Z, Ying P, Dai J, Shi D, Xu Z, et al. Biomarkers of deep venous thrombosis. J Thromb Thrombolysis 2012 Oct;34(3):335-46. DOI: 10.1007/s11239-012-0721-y

  • 28. Eagleton MJ, Henke PK, Luke CE, Hawley AE, Bedi A, Knipp BS, et al. Inflammation and intimal hyperplasia associated with experimental pulmonary embolism. J Vasc Surg 2002;36:581-8. DOI: 10.1067/mva.2002.126556

  • 29. Wakefield TW, Myers DD, Henke PK. Mechanisms of Venous Thrombosis and Resolution. Arterioscler Thromb Vasc Biol 2008;28:387-91. DOI: 10.1161/ATVBAHA. 108.162289

  • 30. Lang IM, Dorfmuller P, Vonk Noordegraaf A. The Pathobiology of Chronic Thromboembolic Pulmonary Hypertension. Ann Am Thorac Soc 2016 Jul;13 Suppl 3:S215-21. DOI: 10.1513/AnnalsATS.201509-620AS

  • 31. Roumen-Klappe EM, Janssen MCH, van Rossum J, Holewijn S, van Bokhoven MMJA, Kaasjager K, et al. Inflammation in deep vein thrombosis and the development of post-thrombotic syndrome: a prospective study. J Thromb Haemost 2009;7:582-7. DOI: 10.1111/j.1538-7836.2009.03286.x

  • 32. Pesavento R, Prandoni P. Prevention and treatment of the post-thrombotic syndrome and of the chronic thromboembolic pulmonary hypertension. Expert Rev Cardiovasc Ther 2015 Feb;13(2):193-207. DOI: 10.1586/14779072.2015.1000306

  • 33. Evans CE, Grover SP, Humphries J, Saha P, Patel AP, Patel AS, et al. Antiangiogenic Therapy Inhibits Venous Thrombus Resolution. Arterioscler Thromb Vasc Biol 2014;34:565-570. DOI: 10.1161/ATVBAHA. 113.302998

  • 34. Choi KJ, Cha SI, Shin KM, Lim JK, Yoo SS, Lee J, et al. Factors determining clot resolution in patients with acute pulmonary embolism. Blood Coagul Fibrinolysis 2016 Apr;27(3):294-300. DOI: 10.1097/MBC.0000000000000425

  • 35. Alias S, Redwan B, Panzenbock A, Winter MP, Schubert U, Voswinckel R, et al. Defective angiogenesis delays thrombus resolution: a potential pathogenetic mechanism underlying chronic thromboembolic pulmonary hypertension. Arterioscler Thromb Vasc Biol 2014 Apr;34(4):810-9. DOI: 10.1161/ATVBAHA.113.302991

  • 36. Souza-Costa DC, Zerbini T, Palei AC, Gerlach RF, Tanus- Santos JE. L-arginine Attenuates Acute Pulmonary Embolism-Induced Increases in Lung Matrix Metalloproteinase-2 and Matrix Metalloproteinase-9. Chest 2005;128:3705-10. DOI: 10.1378/chest.128.5.3705


Journal + Issues